GSK (LON:GSK) Stock Rating Reaffirmed as Hold by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday, Digital Look reports. They currently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft‘s target price indicates a potential upside of 4.33% from the company’s previous close.

A number of other brokerages have also commented on GSK. Berenberg Bank reiterated a “buy” rating and issued a GBX 2,200 price objective on shares of GSK in a report on Tuesday, November 3rd. Royal Bank Of Canada initiated coverage on GSK in a research note on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 target price for the company. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Tuesday, October 20th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,145.

GSK Stock Up 0.7%

Shares of GSK traded up GBX 12.50 during mid-day trading on Tuesday, reaching GBX 1,917. 4,785,284 shares of the stock traded hands, compared to its average volume of 12,145,941. The stock has a fifty day simple moving average of GBX 1,843.25 and a 200 day simple moving average of GBX 1,950.04. GSK has a 12-month low of GBX 1,690 and a 12-month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.86 and a debt-to-equity ratio of 126.38. The firm has a market cap of £76.85 billion, a price-to-earnings ratio of 17.93, a P/E/G ratio of 1.24 and a beta of 0.28.

GSK (LON:GSK) last announced its earnings results on Wednesday, October 28th. The company reported GBX 54.60 earnings per share for the quarter. The business had revenue of GBX 888.70 billion during the quarter. GSK had a net margin of 12.97% and a return on equity of 24.64%. Sell-side analysts expect that GSK will post 175.98 EPS for the current fiscal year.

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal bought 637 shares of GSK stock in a transaction dated Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Over the last ninety days, insiders acquired 2,151 shares of company stock worth $6,021,921. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.